Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Immunocore Holdings ( (IMCR) ) has provided an announcement.
Immunocore Holdings has appointed Travis Coy as its new Executive Vice President, Chief Financial Officer, and Head of Corporate Development, effective January 1, 2025. Coy transitions from his role as a Non-Executive Director at Immunocore, bringing over 20 years of experience from Eli Lilly where he held numerous leadership positions in finance and business development. This strategic appointment is expected to strengthen Immunocore’s executive team as the company continues its mission to deliver transformative medicines, indicating a focus on expanding its financial and corporate development capabilities.
More about Immunocore Holdings
Immunocore Holdings plc is a commercial-stage biotechnology company that develops transformative immunomodulating medicines targeting cancer, infectious diseases, and autoimmune diseases. The company pioneers TCR bispecific immunotherapies, notably through its ImmTAX platform, and has secured approval for its advanced oncology therapeutic, KIMMTRAK, in various regions.
Average Trading Volume: 278,250
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.48B
For a thorough assessment of IMCR stock, go to TipRanks’ Stock Analysis page.
